Chronic Myelomonocytic Leukemia Microenvironment in Disease Progression and Therapy: Focus on Stepwise Reconfiguring of Myeloid-Immune Cell Interactions Driving Immune Tolerance.

IF 3.3 3区医学 Q2 HEMATOLOGY

Current Hematologic Malignancy Reports Pub Date : 2025-09-26 DOI:10.1007/s11899-025-00757-y

Ali Khalid A Alsugair, Abhishek Mangaonkar

{"title":"Chronic Myelomonocytic Leukemia Microenvironment in Disease Progression and Therapy: Focus on Stepwise Reconfiguring of Myeloid-Immune Cell Interactions Driving Immune Tolerance.","authors":"Ali Khalid A Alsugair, Abhishek Mangaonkar","doi":"10.1007/s11899-025-00757-y","DOIUrl":null,"url":null,"abstract":"Purpose of the review: To summarize evidence and provide an overview of the microenvironment and myeloid-immune cell interactions within the chronic myelomonocytic leukemia (CMML) microenvironment that drive mutation-agnostic pathways of disease progression.Recent findings: Recent work has demonstrated the importance of myeloid-immune cell interactions in CMML and related myeloid neoplasms. In particular, we focus on the bone marrow microenvironment of CMML, highlighting the role of clonal dendritic cell aggregates and their interaction with other myeloid cells such as monocytes and their precursors, and adaptive immune cells. Several drugs are currently under investigation that target the inflammasome, specific immune cell populations, and immune checkpoint inhibitors with limited success as monotherapy. Immune microenvironment plays a critical role in CMML disease biology and can be targeted for therapeutic benefit. Future research should focus on identifying pathways that are indispensable for progression.","PeriodicalId":10852,"journal":{"name":"Current Hematologic Malignancy Reports","volume":"20 1","pages":"11"},"PeriodicalIF":3.3000,"publicationDate":"2025-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Hematologic Malignancy Reports","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11899-025-00757-y","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose of the review: To summarize evidence and provide an overview of the microenvironment and myeloid-immune cell interactions within the chronic myelomonocytic leukemia (CMML) microenvironment that drive mutation-agnostic pathways of disease progression.

Recent findings: Recent work has demonstrated the importance of myeloid-immune cell interactions in CMML and related myeloid neoplasms. In particular, we focus on the bone marrow microenvironment of CMML, highlighting the role of clonal dendritic cell aggregates and their interaction with other myeloid cells such as monocytes and their precursors, and adaptive immune cells. Several drugs are currently under investigation that target the inflammasome, specific immune cell populations, and immune checkpoint inhibitors with limited success as monotherapy. Immune microenvironment plays a critical role in CMML disease biology and can be targeted for therapeutic benefit. Future research should focus on identifying pathways that are indispensable for progression.

查看原文本刊更多论文

慢性髓单细胞白血病微环境在疾病进展和治疗中的作用：关注骨髓-免疫细胞相互作用驱动免疫耐受的逐步重新配置。

综述的目的：总结证据并概述慢性髓单细胞白血病（CMML）微环境中驱动疾病进展突变不可知论途径的微环境和骨髓-免疫细胞相互作用。最近的发现：最近的工作已经证明了髓-免疫细胞相互作用在CMML和相关髓系肿瘤中的重要性。我们特别关注CMML的骨髓微环境，强调克隆树突状细胞聚集体的作用及其与其他骨髓细胞（如单核细胞及其前体）和适应性免疫细胞的相互作用。目前有几种针对炎性体、特异性免疫细胞群和免疫检查点抑制剂的药物正在研究中，但作为单一疗法，成功率有限。免疫微环境在CMML疾病生物学中起着至关重要的作用，可以靶向治疗。未来的研究应该把重点放在确定对进步不可或缺的途径上。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Hematologic Malignancy Reports ONCOLOGY-HEMATOLOGY

CiteScore

6.00

自引率

0.00%

发文量

审稿时长

>12 weeks

期刊介绍： his journal intends to provide clear, insightful, balanced contributions by international experts that review the most important, recently published clinical findings related to the diagnosis, treatment, management, and prevention of hematologic malignancy. We accomplish this aim by appointing international authorities to serve as Section Editors in key subject areas, such as leukemia, lymphoma, myeloma, and T-cell and other lymphoproliferative malignancies. Section Editors, in turn, select topics for which leading experts contribute comprehensive review articles that emphasize new developments and recently published papers of major importance, highlighted by annotated reference lists. An international Editorial Board reviews the annual table of contents, suggests articles of special interest to their country/region, and ensures that topics are current and include emerging research. Commentaries from well-known figures in the field are also provided.